 The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of BuparidPARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis CRS with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients. 